QT Imaging Holdings is offering $9,999,920 of securities consisting of 1,200,000 shares of common stock and pre-funded warrants to purchase up to 800,000 shares of common stock.
The public offering price is $5.00 per share (pre-funded warrant price equals share price minus $0.0001). Underwriting discounts total $699,994.40, and estimated net proceeds to the company are approximately $9.0 million before expenses. The company reported 12,042,500 shares outstanding as of May 14, 2026, and would have approximately 13,242,500 shares outstanding after the offering assuming none of the pre-funded warrants are exercised.
QT Imaging Holdings, Inc. reported sharply higher revenue and a smaller loss for the quarter ended March 31, 2026. Revenue rose to $6.5 million from $2.8 million a year earlier, driven almost entirely by product sales in the United States.
Gross profit increased to $2.7 million, but higher research and development plus selling, general and administrative expenses pushed the operating loss to $2.3 million. Net loss narrowed to $3.4 million from $11.1 million, helped by lower other expenses.
Cash and cash equivalents were $6.9 million, with cash used in operating activities of $3.7 million in the quarter. Total liabilities were $18.2 million and stockholders’ equity fell to $3.8 million from $6.4 million, reflecting ongoing losses and fair value changes in warrant and earnout liabilities.
The company highlighted distribution agreements with minimum order quantities that it believes, together with the Lynrock Lake Term Loan (now maturing in 2029 at 12% interest), PIPE financings, and expected MOQ-related revenue, will fund its operating plan for at least the next 12 months.
QT Imaging Holdings reported strong first quarter 2026 growth, with revenue of $6.5 million, up 133% from $2.8 million a year earlier, driven by shipments of 13 Breast Acoustic CT scanners versus six in the prior-year period.
Gross margin was 41% compared with 65%, reflecting mix effects, while operating expenses rose to $5.0 million from $2.9 million, leading to a net loss of $3.4 million, a notable improvement from $11.1 million. Cash, restricted cash, and cash equivalents were $7.0 million as of March 31, 2026.
The company extended the maturity of its senior secured term loan to March 31, 2029 and increased the interest rate to 12.0% per annum. It also secured a dedicated Category III CPT code effective January 1, 2027, obtained FDA 510(k) clearance for scanner enhancements, and reaffirmed 2026 revenue guidance of approximately $39 million supported by minimum order commitments and a multiyear UAE distribution agreement totaling more than $24 million in scanner revenue.
QT Imaging Holdings, Inc. Schedule 13G/A shows Alta Partners LLC reports beneficial ownership of 540,842 shares of Common Stock, representing 4.3% of the class; these shares are described as issuable upon exercise of warrants. The filing is signed by Steven Cohen as Managing Member on 05/08/2026.
QT Imaging Holdings, Inc. has filed a shelf registration to offer, from time to time, up to $100,000,000 of securities under a base prospectus.
The shelf covers Common Stock, Preferred Stock, Debt Securities, Warrants and Units to be issued in one or more series or combinations, with specific terms to be provided in prospectus supplements. As of March 26, 2026, the Company reported 12,042,500 shares of Common Stock outstanding. The registration statement is a preliminary prospectus dated March 27, 2026 and offerings may not occur until an applicable prospectus supplement is delivered.
QT Imaging Holdings, Inc. updated compensation for its top executives. The Board increased Chief Executive Officer Dr. Raluca Dinu’s annual base salary from $550,000 to $605,000, effective March 20, 2026, and approved a cash bonus of $231,993 for her.
Chief Financial Officer Jay Jennings received a cash bonus of $40,576. The Board also granted Dr. Dinu a total of 519,500 restricted stock units (RSUs), split into grants of 3,500, 16,000 and 500,000 RSUs, vesting in scheduled installments from May 15, 2026 through February 15, 2030, contingent on continued service.
Mr. Jennings received a grant of 2,800 RSUs, with 933 RSUs vesting on May 15, 2027 and the remaining 1,867 RSUs vesting in eight quarterly installments through May 15, 2029, also subject to his continued service with the company.
QT Imaging Holdings reported strong growth for 2025, with revenue of $18.9 million, up from $4.9 million in 2024, driven by shipping a record 40 Breast Acoustic CT scanners. Fourth quarter 2025 revenue was $8.3 million, reflecting 877% year-over-year growth and 97% sequential growth.
Despite this expansion, the company recorded a 2025 net loss of $21.1 million, or $2.01 per share, largely influenced by $8.8 million of other expense tied to debt-related non-cash items and fair value changes. Non-GAAP adjusted EBITDA improved to $(3.5) million from $(7.4) million, showing better underlying performance.
QT Imaging ended 2025 with $10.5 million in cash, restricted cash, and cash equivalents and positive stockholders’ equity of $6.4 million. For 2026, it affirmed revenue guidance of approximately $39 million, more than double 2025, supported by contracted scanner minimum order quantities and initial QTI Cloud Platform revenue.
QT Imaging Holdings, Inc. files its annual report describing a breast imaging business built around its QT Breast Scanner, a 3D ultrasound tomography system that avoids ionizing radiation and breast compression. The device received initial FDA 510(k) clearance in June 2017, an additional quantitative breast density clearance in August 2022, and a further clearance on March 10, 2026 for an enhanced configuration that improves imaging of posterior breast tissue near the chest wall.
The company outlines a strategy to evolve from a hardware maker into a precision imaging platform by adding a cloud SaaS infrastructure and future AI modules for quantitative biomarkers and diagnostic decision support. It targets the breast imaging market, which the report cites at about $6.04 billion globally in 2025, and references broader medical imaging and cancer screening markets. Commercially, QT Imaging has an exclusive U.S. distribution agreement with NXC Imaging, tied to minimum order quantities, and exclusive distribution deals with Gulf Medical Co. in Saudi Arabia and Al Naghi Medical Co. in the UAE. The Al Naghi agreement includes minimum orders totaling 43 scanners from 2026 through 2028, representing more than $24 million in revenue commitments, subject to performance and supply conditions.
Taylor Ross reported acquisition or exercise transactions in this Form 4 filing.
QT Imaging Holdings director Taylor Ross received an equity grant of 3,500 shares of Common Stock on March 20, 2026, at no cash cost. Following this award, Ross directly holds 60,578 shares. The grant is in the form of Restricted Stock Units that vest in four equal installments on May 15, 2026, August 15, 2026, November 15, 2026, and February 15, 2027, subject to continued service. All units vest immediately if there is a Change of Control under the company’s 2024 Equity Incentive Plan.
QT Imaging Holdings director Zeev Weiner increased his stake through equity compensation transactions. On March 17, 2026 he exercised stock options covering 23,054 shares of Common Stock at exercise prices of $2.2452 and $1.9950 per share, retaining the acquired shares. On March 20, 2026 he received a grant of 3,500 shares of Common Stock at no cost, reflecting a restricted stock unit award that vests in four equal installments between May 15, 2026 and February 15, 2027, with full vesting upon a Change of Control. Following these transactions, he directly holds 55,093 shares of Common Stock, and the filing indicates all reported derivative option positions tied to these exercises have been fully exercised.